Publish Time: 2022-02-18 Origin: Site
At present, the number of domestic pet dogs and cats is almost above 150 million, which is very huge, but compared with European and American countries, the number of pets per capita is still relatively low. 65% of American families have a pet. Then China's figure is only 2.5%-2.6%, and the potential of the future consumer market is very huge. In the distribution of pet expenditure, pet food is the most important; Next, pet medicine accounts for more than 22% of the market. Among them, pet medicine is the guarantee of basic life, which is the focus of pet owners and doctors. Therefore, China's pet medicine has become one of the potential market segments, and its development status shows the following characteristics.
Here is the content list:
l Current situation of pet drug.
l Domestic pet drug enterprises and research and development status.
According to the classification of products, the world's largest output is antiparasitic drugs, accounting for 27.5% of pet drugs. Secondly, biological products accounted for 22.6%, and other drugs accounted for 18.5%. Anti-infective drugs accounted for 17%, and feed additives accounted for 14.3%. According to the specific situation in foreign countries, the pet medicine industry in developed countries is relatively mature, with a wide range of pet medicines, and most of them are cutting-edge and efficient special medicines, such as anti-motion sickness medicines, antidepressants, weight-loss medicines for pet dogs, and even contraceptives specially developed for dogs. Comparatively speaking, the domestic pet medicine industry started late, and most veterinary drug enterprises only produce drugs for livestock and poultry. As a small branch of veterinary drugs, the market demand for pet tablets was relatively small before, so it did not develop effectively. Lack of cutting-edge and efficient pet-specific drugs, almost 70% of drugs in the domestic market are monopolized by foreign products. Facing the shortage of the pet market, China is actively adjusting and optimizing the veterinary drug industry structure. At the same time, to promote the development of pet tablets, in April 2017, the ministry of Agriculture sorted out and published a list of drugs that can be used for pets, totaling 182 varieties, including some traditional Chinese medicines. However, compared with foreign products, these drugs are far from meeting the growing drug demand of pet owners, and the varieties of pet medical drugs need to be enriched and supplemented urgently.
Domestic pet medicine enterprises are in a state of "small, weak, and scattered" as a whole. There are few enterprises specializing in pet medicine production, and most of them are small in scale and weak in strength. The pet drugs produced by our company have strong homogeneity, a high degree of mutual imitation, and weak market competitiveness, which makes it difficult for enterprises to obtain economies of scale. Without good benefits, we can't afford the cost and risk of researching and developing innovative new drugs. In addition, there is a lack of talents specializing in the research and development of pet drugs, and few enterprises with the strength to conduct independent research and development. At the same time, there is a lack of R&D innovation platforms for pet drugs, and it is difficult for research institutes and universities to combine R&D with enterprise production, and the integration of Industry-University-Research is out of touch. Although the domestic pet medicine industry, especially pet medicine, has some shortcomings, its high-speed and sustainable development has greatly encouraged our employees. With the gradual standardization and establishment of domestic diagnosis and treatment level, R&D technology, laws and regulations, standard system, and law enforcement supervision system, the systems of various pet industries have produced a relatively good cycle. The competitiveness of compliant, efficient, and high-quality drugs is highlighted, and the market rate of return of new drug research and development is relatively high, thus promoting the research and development of pet drugs in China, showing an increasingly good trend and development trend. According to the information disclosed in the 2018 White Paper on China's Pet Industry, the overall scale of China's pet medicine industry reached 170.8 billion yuan in 2018. It is estimated that by 2020, the scale of China's pet market will exceed 200 billion yuan, and China's pet medicine industry will maintain a high annual growth rate of 20.5% during 2017-2020. Pet drugs are commonly used in pet hospitals, and most of them are health products. At present, the category of therapeutic drugs is relatively single. The sales of pet drugs in 2016 reached 14.7 billion yuan, accounting for 12% of the industrial scale. Influenced by factors such as low investment in pet drug production technology and R&D expenses, the quality of domestic pet drugs is different, and there are too few well-known brands in the industry.
If you are interested in pet medicine or want to buy a pet oral solution or pet powder, pet injection. Our official website is https://www.topsurfholding.com/products.html. You can communicate with us on the website. We look forward to serving you.